Brief: Pepgen Presents Clinical And Nonclinical Data At The 2023 Annual Muscular Dystrophy Association Clinical And Scientific Conference
BofA ups PepGen's PT on lead drug prospects
PepGen climbs as H.C. Wainwright starts coverage with 'buy'
Brief: PepGen Announces IND-Enabling Preclinical Data Supporting Progression Of PGN-EDODM1 Into Clinical Studies
Brief: Pepgen Announces Positive Preclinical Data For Pgn-Edo53, Pgn-Edo45 And Pgn-Edo44, Three Novel Duchenne Muscular Dystrophy Candidates
U.S. STOCKS ON THE MOVE-Heartbeam, Aura Biosciences, U.S. banks
PepGen soars after lead drug candidate shows promise in trial
Brief: PepGen Reports Positive Data From Phase 1 Trial Of PGN-EDO51 For Treatment Of Duchenne Muscular Dystrophy
Brief: Pepgen Appoints Habib Dable To Board Of Directors
Brief: Pepgen Reports Q2 2022 Financial Results
Brief: PepGen Inc Shares Open 30% Above IPO Price In Nasdaq Debut
Biotech co PepGen's shares leap in Nasdaq debut
Brief: PepGen Ltd Shares Open 30% Above IPO Price In Nasdaq Debut
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 04:00 AM
Brief: Pepgen Announces Pricing Of 9 Mln Shares Of Common Stock At An IPO Price Of $12.00/SHR